Positive News SentimentPositive NewsNASDAQ:AVXL Anavex Life Sciences (AVXL) Stock Price, News & Analysis $2.54 -0.08 (-3.05%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$2.54 0.00 (0.00%) As of 06/9/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Anavex Life Sciences Stock (NASDAQ:AVXL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anavex Life Sciences alerts:Sign Up Key Stats Today's Range$2.47▼$2.7350-Day Range$2.54▼$3.6552-Week Range$2.47▼$13.99Volume868,971 shsAverage Volume1.15 million shsMarket Capitalization$235.38 millionP/E RatioN/ADividend YieldN/APrice Target$21.33Consensus RatingHold Company Overview Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need. The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia. Anavex also holds ANAVEX3‐71, a muscarinic receptor agonist, in its pipeline for Rett syndrome and other developmental disorders. Through these programs, the company aims to demonstrate disease‐modifying effects by addressing underlying cellular dysfunction rather than solely managing symptoms. Since its founding in 2012, Anavex has completed multiple Phase I and Phase II trials in North America and Europe, collaborating with academic research centers and contract research organizations to support its clinical development. The company has established manufacturing partnerships to ensure supply of clinical‐grade API and plans to expand its trial network into additional regions as programs advance. Christopher U. Missling serves as President and CEO, bringing more than two decades of experience in pharmaceutical research and development. Under his leadership, Anavex continues to explore strategic collaborations and funding opportunities to propel its pipeline toward regulatory milestones.AI Generated. May Contain Errors. Read More Anavex Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreAVXL MarketRank™: Anavex Life Sciences scored higher than 42% of companies evaluated by MarketBeat, and ranked 746th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingAnavex Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnavex Life Sciences has a consensus price target of $21.33, representing about 739.9% upside from its current price of $2.54.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Anavex Life Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.33) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anavex Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.84% of the float of Anavex Life Sciences has been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 16.63, which indicates bearish sentiment.Change versus previous monthShort interest in Anavex Life Sciences has recently decreased by 2.07%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentAnavex Life Sciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Anavex Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.55% of the stock of Anavex Life Sciences is held by institutions.Read more about Anavex Life Sciences' insider trading history. Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVXL Stock News HeadlinesAnavex Life Sciences Corp. Receives Delinquency Notification from Nasdaq for Non-Compliance with Listing RuleMay 22, 2026 | quiverquant.comQAnavex Life Sciences Receives Expected Nasdaq Delinquency NotificationMay 22, 2026 | globenewswire.comTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway. | Porter & Company (Ad)Anavex Life Sciences Announces COO Departure Amid RestructuringMay 15, 2026 | tipranks.comCEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in FocusMay 6, 2026 | finance.yahoo.comAnavex slips after CEO transitionMay 6, 2026 | seekingalpha.comAnavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive OfficerMay 6, 2026 | globenewswire.comWhat Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny StocksApril 26, 2026 | finance.yahoo.comSee More Headlines AVXL Stock Analysis - Frequently Asked Questions How have AVXL shares performed this year? Anavex Life Sciences' stock was trading at $3.56 at the start of the year. Since then, AVXL stock has decreased by 28.7% and is now trading at $2.54. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) released its quarterly earnings results on Monday, February, 9th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04. Read the conference call transcript. Who are Anavex Life Sciences' major shareholders? Top institutional investors of Anavex Life Sciences include Bank of America Corp DE (0.93%), Private Advisor Group LLC (0.54%), Renaissance Technologies LLC (0.30%) and Bank of New York Mellon Corp (0.27%). Insiders that own company stock include Christopher U Missling, Steffen Thomas and Peter DO Donhauser. View institutional ownership trends. How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anavex Life Sciences investors own include Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Innovative Industrial Properties (IIPR), Voya Infrastructure, Industrials and Materials Fund (IDE), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings2/09/2026Today6/09/2026Next Earnings (Estimated)6/09/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 AVXL's financial health is in the Yellow zone, according to TradeSmith. AVXL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVXL CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees40Year Founded2006Price Target and Rating Average Price Target for Anavex Life Sciences$21.33 High Price Target$24.00 Low Price Target$20.00 Potential Upside/Downside+739.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.76% Return on Assets-35.01% Debt Debt-to-Equity RatioN/A Current Ratio20.87 Quick Ratio20.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book2.31Miscellaneous Outstanding Shares92,670,000Free Float82,478,000Market Cap$235.38 million OptionableOptionable Beta1.20 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:AVXL) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
